AbbVie Inc (ABBV)vsProtalix Biotherapeutics Inc (PLX)
ABBV
AbbVie Inc
$263.96
-0.02%
HEALTHCARE · Cap: $454.36B
PLX
Protalix Biotherapeutics Inc
$2.69
-0.37%
HEALTHCARE · Cap: $219.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 79765% more annual revenue ($64.39B vs $80.62M). PLX leads profitability with a 23.5% profit margin vs 9.8%. PLX trades at a lower P/E of 11.4x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PLX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$263.96
$111.80 premium
Intrinsic value data unavailable for PLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 2241.0% YoY
Every $100 of equity generates 23 in profit
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 23.5%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : PLX
The strongest argument for PLX centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.5% and operating margin at 23.5%. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
ABBV profiles as a value stock while PLX is a growth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
PLX is growing revenue faster at 27.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 64/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?